📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Loading analysis...
Laurus Labs Appoints Two New Independent Directors for 5-Year Terms Starting July 2026
Laurus Labs has announced the appointment of Dr. Shekhar Chintamani Mande and Ms. Sutapa Banerjee as Independent Directors for five-year terms starting July 02, 2026. Dr. Mande is a distinguished scientist and former Director General of CSIR, while Ms. Banerjee brings over 30 years of experience in global financial services and wealth management. These appointments coincide with the retirement of Mrs. Aruna Bhinge, who will complete her second term on July 06, 2026. The addition of high-caliber experts from scientific and financial domains is expected to strengthen the board's strategic oversight.
Key Highlights
Dr. Shekhar Chintamani Mande appointed as Independent Director for a 5-year term effective July 02, 2026.
Ms. Sutapa Banerjee appointed as Independent Director for a 5-year term effective July 02, 2026.
Mrs. Aruna Bhinge to retire on July 06, 2026, after completing two full terms as an Independent Director.
New directors bring expertise from the Council of Scientific and Industrial Research (CSIR) and major banks like ANZ Grindlays and ABN AMRO.
💼 Action for Investors
Investors should view these appointments as a positive step toward enhancing corporate governance and technical expertise at the board level. No immediate action is required as these changes are part of routine board succession planning.
Loading analysis...
Laurus Labs to Invest EUR 9.8 Million in KRKA Pharma JV for New Manufacturing Facility
Laurus Labs has approved an additional investment of up to EUR 9.8 million in its joint venture, KRKA Pharma Private Limited. The Slovenian co-venturer, KRKA d.d., will also invest approximately EUR 10.2 million, maintaining the existing 49:51 shareholding ratio. These funds are specifically designated for capital expenditure to establish a new manufacturing facility in India. The JV, incorporated in 2024, is currently providing R&D services and reported a turnover of INR 10.47 million in FY26.
Key Highlights
Laurus Labs to invest up to EUR 9.8 million (approx. INR 88-90 Cr) in KRKA Pharma JV
Co-venturer KRKA d.d. Slovenia to invest EUR 10.2 million to maintain 51% stake
Investment proceeds will be used for setting up a new manufacturing facility
Laurus Labs will maintain its 49% equity stake in the joint venture
The investment is scheduled to be completed during the financial year 2026-27
💼 Action for Investors
This expansion signals a commitment to long-term growth and capacity building in partnership with a global pharma player. Investors should view this as a positive strategic move, though the financial benefits will only materialize once the new facility becomes operational.
Loading analysis...
Laurus Labs Appoints Dr. Shekhar Mande and Ms. Sutapa Banerjee as Independent Directors
Laurus Labs has announced the appointment of two high-profile Independent Directors, Dr. Shekhar Chintamani Mande and Ms. Sutapa Banerjee, for five-year terms starting July 2, 2026. Dr. Mande is a renowned scientist and former Director General of CSIR, while Ms. Banerjee is a veteran in financial services and wealth management. These appointments follow the scheduled retirement of Mrs. Aruna Bhinge on July 6, 2026, after a 10-year tenure. The inclusion of such experts is expected to bolster the company's strategic oversight in R&D and financial governance.
Key Highlights
Dr. Shekhar Chintamani Mande appointed as Independent Director for a 5-year term starting July 2, 2026.
Ms. Sutapa Banerjee appointed as Independent Director for a 5-year term starting July 2, 2026.
Mrs. Aruna Bhinge to retire on July 6, 2026, after completing two consecutive 5-year terms.
New directors bring significant expertise from CSIR (scientific research) and top-tier banking/wealth management.
💼 Action for Investors
The addition of a top scientist and a finance veteran to the board strengthens corporate governance and strategic depth. Investors should view this as a positive development for the company's long-term oversight.
Loading analysis...
Laurus Labs Declares 2nd Interim Dividend of Rs 1.20 per Share; Record Date May 08
Laurus Labs has approved a second interim dividend of Rs 1.20 per equity share for the financial year 2025-26, which represents 60% of the face value of Rs 2. The company has designated May 08, 2026, as the record date to identify eligible shareholders for this distribution. The dividend is scheduled to be paid to shareholders on or after May 20, 2026. This move reflects the company's continued commitment to returning value to its shareholders during the fiscal year.
Key Highlights
Approved 2nd interim dividend of Rs 1.20 per equity share for FY 2025-26
Dividend payout represents 60% of the face value of Rs 2 per share
Record date for determining shareholder eligibility is fixed as May 08, 2026
Dividend payment will be processed on or after May 20, 2026
💼 Action for Investors
Investors looking to benefit from this dividend should ensure they hold the stock before the ex-dividend date, which is typically one business day before the May 08 record date. Long-term investors should monitor the company's overall payout ratio and earnings growth to assess dividend sustainability.
Loading analysis...
Laurus Labs FY26 Net Profit Surges 148% to ₹889 Cr; CDMO Revenue Grows 36%
Laurus Labs reported a robust performance for FY26, with total revenues growing 23% to ₹6,813 crore, driven by a 36% surge in the CDMO segment. Net profit witnessed a massive 148% increase to ₹889 crore, supported by a significant expansion in EBITDA margins to 26.8% from 20.1% in the previous year. The company is successfully de-risking its portfolio by reducing dependence on ARV APIs and increasing its high-margin CDMO and generic FDF contributions. With a ₹1,070 crore capex in FY26 and a long-term $600 million investment plan for a new Vizag site, the company is positioning itself for sustained high-tech pharmaceutical growth.
Key Highlights
FY26 Revenue grew 23% YoY to ₹6,813 Cr, with CDMO segment contributing 31% of total revenue mix.
Net Profit jumped 148% to ₹889 Cr, while EBITDA margins expanded by 670 bps to 26.8%.
Net Debt-to-EBITDA significantly improved to 1.3x from 2.3x in the previous year due to better cash flows.
Company executed ₹1,070 Cr in Capex during FY26, focusing on ADC, Gene Therapy, and Peptides.
ROCE nearly doubled to 17.7% in FY26 compared to 9.7% in FY25, reflecting improved operating leverage.
💼 Action for Investors
Investors should view the strong margin recovery and the strategic shift towards the high-growth CDMO segment as positive long-term catalysts. The significant reduction in leverage and improved ROCE suggest the company's heavy investment phase is beginning to yield high-quality returns.
Loading analysis...
Laurus Labs to Invest €9.8M in KRKA JV for Capex; Appoints New Independent Directors
Laurus Labs has approved an investment of up to €9.8 million in its joint venture, KRKA Pharma Private Limited, to fund the construction of a new manufacturing facility. The co-venturer, KRKA d.d., will also invest €10.2 million, ensuring the 51:49 shareholding ratio remains unchanged. Simultaneously, the company is strengthening its board by appointing Dr. Shekhar Chintamani Mande and Ms. Sutapa Banerjee as Independent Directors. The board also approved the closure of its non-operational German subsidiary, which had zero revenue in FY26, to streamline operations.
Key Highlights
Investment of up to €9.8 million in KRKA Pharma JV to fund a new manufacturing plant.
JV partner KRKA d.d. to invest €10.2 million, maintaining Laurus Labs' 49% stake.
Appointment of Dr. Shekhar Mande (ex-DG, CSIR) and Ms. Sutapa Banerjee as Independent Directors for 5-year terms.
Voluntary closure of Laurus Generics GmbH (Germany) which reported zero turnover in FY26.
KRKA Pharma JV reported a turnover of INR 10.47 million in FY26 during its R&D phase.
💼 Action for Investors
Investors should view the JV investment as a positive step toward long-term capacity expansion and strategic growth. The addition of high-profile independent directors further strengthens corporate governance and technical oversight.
Loading analysis...
Laurus Labs FY26 Net Profit Surges 151% to ₹890 Cr; Declares ₹1.20 Interim Dividend
Laurus Labs reported a robust financial performance for the fiscal year ended March 31, 2026, with annual consolidated revenue growing 23% to ₹6,812.90 crore. The company's net profit for FY26 saw a massive jump of 151%, reaching ₹889.85 crore compared to ₹354.41 crore in the previous year. For the fourth quarter alone, net profit stood at ₹281.91 crore, nearly a four-fold increase from the ₹73.45 crore reported in Q4 FY25. Additionally, the board has approved a second interim dividend of ₹1.20 per share, rewarding shareholders for the strong performance.
Key Highlights
Annual Consolidated Revenue increased by 22.7% YoY to ₹6,812.90 crore in FY26.
Full-year Net Profit grew by 151% YoY to ₹889.85 crore from ₹354.41 crore in FY25.
Q4 FY26 Net Profit rose to ₹281.91 crore, a significant jump from ₹73.45 crore in the year-ago quarter.
Declared a 2nd interim dividend of ₹1.20 per share (60% of face value) with a record date of May 08, 2026.
Earnings Per Share (EPS) for FY26 improved significantly to ₹16.47 from ₹6.65 in the previous fiscal.
💼 Action for Investors
The significant turnaround in profitability and strong revenue growth indicate that the company's expansion and operational strategies are yielding high returns. Investors should consider holding the stock as the company demonstrates strong operational leverage and consistent dividend payouts.
Loading analysis...
Laurus Labs Clarifies Filing Lapses; Reports Strong Q2 FY26 Net Profit of ₹194.49 Cr
Laurus Labs has responded to NSE's clarification request regarding technical discrepancies in its September 2025 financial filings, attributing them to portal glitches and inadvertent selection errors. Despite these procedural lapses, the company's financial performance for Q2 FY26 shows a significant recovery, with revenue growing to ₹1,653.47 crore from ₹1,223.70 crore YoY. Net profit surged to ₹194.49 crore compared to just ₹19.95 crore in the previous year's corresponding quarter. The company has also confirmed an interim dividend of ₹0.80 per share.
Key Highlights
Revenue from operations increased 35% YoY to ₹1,653.47 crore for the quarter ended September 30, 2025
Net profit witnessed a massive jump to ₹194.49 crore in Q2 FY26 from ₹19.95 crore in Q2 FY25
Board approved an interim dividend of ₹0.80 per equity share (40% of face value) for FY 2025-26
Company rectified XBRL filing discrepancies and submitted revised machine-readable financial results
H1 FY26 total income reached ₹3,260.43 crore, a significant rise from ₹2,425.72 crore in H1 FY25
💼 Action for Investors
Investors should view the regulatory clarification as a resolution of minor procedural issues. The core focus remains on the company's strong earnings turnaround and significant profit growth, which supports a positive long-term outlook.
Loading analysis...
Laurus Labs Receives NCLT Approval for Subsidiary Restructuring and Amalgamation
Laurus Labs has received approval from the NCLT Amravati Bench for its Composite Scheme of Arrangement involving two wholly-owned subsidiaries. The plan involves demerging Unit-1 of Laurus Synthesis Private Limited (LSPL) into Sriam Labs and merging the remaining LSPL business directly into Laurus Labs Limited. The NCLT has dispensed with meetings for shareholders and creditors of the parent company, significantly streamlining the regulatory path. Meetings for unsecured creditors of the subsidiaries are now scheduled for April 06, 2026, to move the process toward final completion.
Key Highlights
NCLT Amravati Bench allowed the First Motion Application for the scheme on February 24, 2026
Unit-1 of Laurus Synthesis Private Limited to be demerged and merged into Sriam Labs Private Limited
Remaining business undertakings of LSPL to be amalgamated with the parent company, Laurus Labs Limited
Meetings of Equity Shareholders and all Creditors of the parent company (Laurus Labs) have been dispensed with
Meetings for Unsecured Creditors of LSPL and Sriam Labs are directed to be held on April 06, 2026
💼 Action for Investors
Investors should view this as a positive step toward corporate simplification and operational efficiency. Monitor the outcome of the unsecured creditor meetings in April as the final steps toward full integration of the CDMO business.
Loading analysis...
Laurus Labs Q3 FY26 Revenue Up 26% to ₹1,778 Cr; EBITDA Margins Expand to 27%
Laurus Labs reported a strong Q3 FY26 with revenue growing 26% YoY to ₹1,778 crores, driven by a 37% surge in the generics division. Profitability showed significant improvement as EBITDA margins expanded to 27% and PAT for the 9-month period jumped 388% to ₹610 crores. The company is aggressively investing in high-growth areas like peptides and ADCs, with a planned CAPEX of ₹1,000 crores for both FY26 and FY27. Management maintains a healthy balance sheet with a net debt-to-EBITDA ratio of 1.2x.
Key Highlights
Q3 FY26 Revenue grew 26% YoY to ₹1,778 crores with Gross Margins expanding to 60.9%
Generics division revenue rose 37% to ₹1,327 crores, fueled by ARV volumes and new launches
CDMO segment recorded over 50% growth in the 9-month period, despite a phased Q3 performance of ₹408 crores
Planned CAPEX of ₹1,000 crores for FY26 and FY27 to scale peptide and ADC capabilities
9-month PAT surged 388% YoY to ₹610 crores, with ROCE improving to 18.5%
💼 Action for Investors
Investors should view the margin expansion and strong CDMO growth as positive indicators of a structural shift in the business mix. Monitor the execution of the new fermentation and ADC facilities for long-term value creation.
Loading analysis...
Laurus Labs Q3 Net Profit Surges 174% YoY to ₹252 Cr; EBITDA Margins Expand to 27.3%
Laurus Labs reported a robust Q3 FY26 with revenue growing 26% YoY to ₹1,778 crore, driven by a 37% surge in the Generics division. Profitability saw a massive jump, with Net Profit increasing 174% to ₹252 crore and EBITDA margins expanding by 720 bps to 27.3%. For the 9M FY26 period, the company crossed the ₹5,000 crore revenue mark with a 104% growth in EBITDA. While the CDMO segment showed 43% growth in the 9M period, the Bio segment faced temporary scale-up challenges with a 9% decline.
Key Highlights
Q3 FY26 Net Profit grew 174% YoY to ₹252 Cr, while 9M FY26 Net Profit surged 388% to ₹610 Cr
EBITDA margins improved significantly to 27.3% in Q3, up from 20.1% in the previous year
9M FY26 Revenues reached ₹5,001 Cr (+30% YoY), supported by strong performance in CDMO and Generics
Net Debt leverage improved to 1.2x EBITDA despite ongoing CAPEX at 15% of sales
Generics division revenue grew 37% in Q3, led by higher ARV volumes and developed market offtake
💼 Action for Investors
Investors should focus on the significant margin expansion and debt reduction as signs of high operational efficiency. The strong 9M performance and the company's strategic shift toward high-value CDMO projects and Peptides/ADC platforms provide a positive long-term outlook.
Loading analysis...
Laurus Labs Q3 FY26 Net Profit Surges 174% to ₹252 Cr; 9M Revenue Hits ₹5,001 Cr
Laurus Labs reported a robust performance for 9M FY26, with revenues growing 30% YoY to ₹5,001 crore and net profit jumping 388% to ₹610 crore. The growth was primarily driven by the CDMO division, which saw 43% growth in the nine-month period, and strong execution in the Generics segment. EBITDA margins expanded significantly to 26.1% for 9M FY26, up from 16.6% in the previous year, aided by a better product mix and operational leverage. The company continues its aggressive CAPEX plan, investing ₹735 crore in 9M FY26 towards new technologies like peptides and gene therapy.
Key Highlights
9M FY26 Revenue grew 30% YoY to ₹5,001 Cr, while Net Profit skyrocketed 388% to ₹610 Cr.
EBITDA margins improved by 950 bps to 26.1% in 9M FY26 due to better product mix and scale.
CDMO Small Molecules segment grew 50% in 9M FY26, despite a muted Q3 due to campaign timing.
Net Debt-to-EBITDA significantly reduced to 1.2x from 3.1x a year ago, showing improved financial health.
Cumulative CAPEX for FY22-26 is projected at ~₹3,900 Cr, focusing on high-growth areas like Peptides and ADCs.
💼 Action for Investors
Investors should take note of the significant margin expansion and the sharp reduction in leverage, which indicate a strong operational turnaround. The company's transition towards high-value CDMO projects and new modalities like gene therapy provides a positive long-term outlook.
Loading analysis...
Laurus Labs Q3 FY26 Net Profit Surges 172% YoY to ₹251.66 Cr; Revenue Up 25.7%
Laurus Labs reported a robust performance for the quarter ended December 31, 2025, with consolidated revenue from operations growing 25.7% YoY to ₹1,778.29 crore. Net profit for the quarter witnessed a massive jump of 172.6% YoY, reaching ₹251.66 crore compared to ₹92.30 crore in the same period last year. The nine-month profit for FY26 also showed significant improvement, rising to ₹609.65 crore from ₹124.65 crore YoY. During the quarter, the company also completed strategic investments in Laurus Bio (₹35 crore) and a joint venture with KRKA Pharma (₹49 crore).
Key Highlights
Consolidated Revenue from operations increased by 25.7% YoY to ₹1,778.29 crore in Q3 FY26.
Net Profit after tax surged by 172.6% YoY to ₹251.66 crore for the quarter.
Basic Earnings Per Share (EPS) improved significantly to ₹4.67 from ₹1.71 in the previous year's quarter.
Company invested ₹49 crore for a 49% stake in KRKA Pharma Private Limited joint venture during the quarter.
Nine-month total income reached ₹5,044.48 crore, a substantial increase from ₹3,850.19 crore in the prior year period.
💼 Action for Investors
The strong recovery in both top-line and bottom-line figures suggests a significant turnaround in operational efficiency and market demand. Investors should maintain a positive outlook while monitoring the progress of the pending NCLT approval for the internal demerger and merger scheme.
Loading analysis...
Laurus Labs Invests ₹49 Crore in KRKA Pharma JV via Rights Issue
Laurus Labs Limited has completed an investment of INR 490 million in its joint venture, KRKA Pharma Private Limited. The company acquired 49,000,000 equity shares at a face value of INR 10 per share through a rights issue. This transaction follows the initial proposal announced on July 25, 2025. The investment demonstrates Laurus Labs' commitment to strengthening its strategic partnership and operational footprint within the JV.
Key Highlights
Invested INR 490,000,000 (₹49 Crores) in KRKA Pharma Private Limited
Acquired 49,000,000 equity shares at a face value of ₹10 each
Investment executed via a rights issue to maintain or increase stake in the JV
Follow-up to the regulatory disclosure originally made in July 2025
💼 Action for Investors
Investors should view this as a strategic move to bolster the company's joint venture capabilities. Monitor future earnings reports for the operational performance and contribution of KRKA Pharma to the consolidated bottom line.
Loading analysis...
Laurus Labs Invests ₹49 Crore in KRKA Pharma JV via Rights Issue
Laurus Labs has completed an investment of ₹490 million (₹49 crore) in its joint venture, KRKA Pharma Private Limited. The company acquired 49 million equity shares at a face value of ₹10 each through a rights issue. This transaction follows the initial proposal announced on July 25, 2025. The capital infusion is aimed at strengthening the joint venture's operations and supporting its strategic objectives.
Key Highlights
Invested INR 490 million (₹49 crore) in KRKA Pharma Private Limited
Acquired 49 million equity shares at a face value of ₹10 per share
The investment was executed through a rights issue mechanism
KRKA Pharma is an existing joint venture of Laurus Labs
💼 Action for Investors
Investors should view this as a strategic commitment to the company's joint venture operations and monitor the JV's future contribution to the consolidated bottom line.